Clean Science & Technology Ltd

- There is no explicit mention of any current or planned fundraising through debt or equity in the transcript. - The company has INR450 crores of cash on hand as of now, indicating a strong cash position. - Capital expenditure projects (capex) have proceeded with minor delays but within anticipated costs, funded primarily via internal resources or existing investments. - The promoter group (Boob family) shows strong engagement with no planned share dilution or offer-for-sale expected beyond the current lock-in period. - The company seems focused on organic growth through product development and market expansion rather than external fundraising at this time.

- Hydroquinone and catechol plants were commercialized in December; customer trials ongoing. - Capex for Performance Chemical 2 is on plan; commercialization expected in Q1 FY '27 (around May-June). - Performance Chemical 2 will start generating staggered revenues from Q4 FY '27. - Performance Chemical 1 running at ~80% capacity utilization; expected revenue INR 260 crores in FY '27 (down from earlier estimate of INR 320 crores) due to reduced prices. - Capex investments amount to around INR 1.5 billion each for Performance Chemical 1 and 2. - The expansion of TBHQ and in-house production of hydroquinone expected to moderate raw material costs and improve margins. - Ongoing R&D to bring new products online and diversify product portfolio. - Total investment in subsidiary Clean Fino Chem Ltd. around INR 700 crores, with INR 150 crores infused in the last 9 months. Overall, capex activities continue with some delays but aligned to strategic growth plans.

- Performance Chemical 1 plant started producing in-house hydroquinone and catechol; sales to start from February with growth expected in March FY '27. - Performance Chemical 2 plant commissioning delayed to May-June FY '27; revenue generation anticipated from Q4 FY '27. - HALS business showing strong growth, with 55% Y-o-Y volume increase; expected to sustain momentum in coming years. - New product commercialization (hydroquinone and catechol) will lower raw material costs and enhance margins. - Efforts ongoing to improve process efficiencies and bring more products online, aiming for volume growth and margin improvement. - Domestic and international demand expected to recover post current macroeconomic challenges. - Trade deal with Europe starting in FY '27 to potentially reduce tariffs (5.5%-12%), helping competitiveness against China. - Expanding export efforts (e.g., catechol exports to China starting February FY '27). - Overall growth and margin recovery expected over 5-year strategic horizon despite short-term uncertainties.

- The company anticipates margin improvement and revenue growth by launching new products and maintaining disciplined capex cycles. - Performance Chemical 2 project commissioning is expected by Q1 FY27, with revenue generation starting in Q4 FY27, albeit staggered. - HALS business is growing steadily, showing a 55% Y-o-Y volume growth this quarter, aiming for 50% utilization over two years. - EBITDA margins faced pressure due to tariffs, pricing pressures, and Chinese competition; recovery depends on market conditions and volume growth. - Operating leverage and cost optimization efforts could aid margin improvements if pricing stabilizes. - Macroeconomic uncertainties and tariffs continue to impact near-term profitability. - The company follows a long-term 5-year strategy focusing on product diversification and retention of market share. - No explicit EPS guidance given, but management is confident about eventually restoring profitability.

The transcript provided does not explicitly mention the current or expected order book or pending orders for Clean Science and Technology Limited. However, relevant insights include: - Performance Chemical 2 plant commercialisation is expected in Q1 FY'27, with production delayed to May from the initially planned March. - New products, including hydroquinone and catechol, were commercialized in December, with customer trials ongoing and exports commencing from February. - Demand challenges are noted due to tariffs and Chinese competition affecting sales volume, but the company aims to retain market share. - New samples of Pharma intermediate DHDT have been sent to customers; outcomes awaited in coming weeks. - The Europe-India trade deal expected to positively impact business beginning in 2027 due to tariff reductions. No specific quantified details on current or pending orders or order book values are provided in the transcript.